What Diseases Is Bosulif Patented For?
Bosulif (bosutinib) is patented primarily for treating chronic myeloid leukemia (CML), a cancer of white blood cells caused by the Philadelphia chromosome. U.S. Patent 7,342,013 covers bosutinib for inhibiting BCR-ABL kinase activity, directly targeting CML where this mutation drives uncontrolled cell growth.[1] This patent, held by Pfizer, expired in 2023, but related formulation and method-of-use patents extend protection.[2]
When Do Key Bosulif Patents Expire?
The core composition-of-matter patent (US 7,342,013) expired December 2023. Method-of-use patents for CML treatment, like US 8,461,173 (covering once-daily dosing), run until 2027-2031. Pediatric exclusivity adds six months to some, pushing effective expiry to mid-2032. Check DrugPatentWatch.com for the latest litigation updates and Paragraph IV challenges.[3]
Has Bosulif Been Patented for Other Diseases?
No FDA-approved indications beyond CML exist, and patents focus exclusively on CML subtypes (chronic, accelerated, or blast phase). Pfizer has not secured patents for other cancers like solid tumors, despite early research into broader kinase inhibition. Off-label use lacks patent protection.[1][2]
Why Focus Patents on CML Only?
Bosutinib's design targets the BCR-ABL fusion protein unique to Philadelphia chromosome-positive CML (about 95% of cases). Broader patents were not pursued due to limited efficacy in other BCR-ABL-negative leukemias or cancers, per clinical data.[4]
Are Generic or Biosimilar Versions Coming Soon?
With the 2023 expiry, ANDA filers like MSN Laboratories and Dr. Reddy's have challenged remaining patents via Paragraph IV certifications. Launch likely delayed until 2027-2028 if settlements hold; full generic entry expected post-2031.[3]
[1] U.S. Patent 7,342,013
[2] FDA Orange Book for Bosulif
[3] DrugPatentWatch.com - Bosulif Patents
[4] Bosulif Prescribing Information